Medical devices maker Merit Medical's Q3 rev beats estimates on strength in cardiac intervention segment

Merit Medical Systems

30/10/2025 20:53

Overview

Merit Medical Q3 revenue grows 13% yr/yr, beating analyst expectations

Adjusted EPS for Q3 beats consensus, rising 6.7% yr/yr

Company raises 2025 revenue and non-GAAP EPS guidance, citing strong Q3 results

Outlook

Merit Medical raises 2025 revenue guidance to $1.502 bln - $1.515 bln

Company updates 2025 non-GAAP EPS guidance to $3.66 - $3.79

Merit Medical expects stable constant currency growth and improving profitability

Result Drivers

CARDIAC INTERVENTION GROWTH - Cardiac Intervention segment revenue increased by 29.3%, contributing significantly to overall revenue growth

OPERATING MARGIN IMPROVEMENT - Non-GAAP operating margin improved to 19.7% from 19.2% in the prior year period

CEO COMMENTARY - CEO Martha G. Aronson attributed strong Q3 performance to effective execution and stable growth

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$384.20 mln
$371.90 mln (11 Analysts)
Q3 Adjusted EPS
Beat
$0.92
$0.83 (10 Analysts)
Q3 EPS
$0.46
Q3 Adjusted Net Income
Beat
$54.90 mln
$50 mln (9 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Merit Medical Systems Inc is $103.50, about 21.4% above its October 29 closing price of $81.39

Press Release: ID:nGNX8QL9gF

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)